Question · asked by 1 review

TNF‐alpha antagonists vs placebo: IBDQ at weeks 6 or 8

TNF‐alpha antagonists leads to higher improved IBDQ at weeks 6 or 8 compared with placebo (high certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
TNF‐alpha antagonists vs placebo
Improved IBDQ at weeks 6 or 8 · patients with active ulcerative colitis
TNF‐alpha antagonists leads to higher improved IBDQ at weeks 6 or 8 compared with placebo (high certainty).
The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane Headline outcomes only
RR 1.32 [1.19, 1.46]3 studies · 1495 participantsHigh
TNF‐alpha antagonists vs placebo
IBDQ at weeks 6 or 8 · patients with active ulcerative colitis
The impact of biological interventions for ulcerative colitis on health‐related quality of life (2015) · Cochrane Headline outcomes only
no estimate extracted4 studies · 1565 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
The impact of biological interventions for ulcerative colitis on health‐related quality of life
2015 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.